931 |
MEMBRANE SPANNING 4-DOMAINS A1 |
MS4A1 |
B1 |
Bp35 |
CD20 |
CVID5 |
LEU-16 |
MS4A2 |
S7 |
112210 |
7315 |
ENSG00000156738 |
OTTHUMG00000167614 |
CD_antigen=CD20 |
Leukocyte surface antigen Leu-16 |
B-lymphocyte surface antigen B1 |
B-lymphocyte antigen CD20 |
Membrane-spanning 4-domains subfamily A member 1 |
P11836 |
CD20_HUMAN |
PA31111 |
T73215 |
FMC7 |
Target Subclass | Unknown_function |
Target Main Class | Other |
Target Subclass | MS4A |
Transmembrane Helix Count | 4 |
Target Class | Other |
Target Class | Miscellaneous |
Target Subclass | MS4A family |
Gene Biotype | PROTEIN_CODING |
CELL SURFACE |
EXTERNAL SIDE OF PLASMA MEMBRANE |
DRUGGABLE GENOME |
antibody (inhibitory) |
inhibitor (inhibitory) |
Trial Name | tositumomab,Bexxar |
Novel drug target | Established target |
Mechanism of Interaction | B-lymphocyte antigen CD20 inhibitor |
antibody (inhibitory) |
inhibitor (inhibitory) |
Trial Name | HuMax-CD20 |
Novel drug target | Established target |
Mechanism of Interaction | B-lymphocyte antigen CD20 inhibitor |
antibody (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | B-lymphocyte antigen CD20 inhibitor |
Direct Interaction | yes |
Trial Name | afutuzumab, R-7159, GA-101 |
antibody (inhibitory) |
antagonist (inhibitory) |
Trial Name | ocrelizumab |
Novel drug target | Established target |
Mechanism of Interaction | B-lymphocyte antigen CD20 other |
n/a |
Trial Name | - |
Novel drug target | Established target |
antibody (inhibitory) |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | B-lymphocyte antigen CD20 inhibitor |
antibody (inhibitory) |
Mechanism of Interaction | B-lymphocyte antigen CD20 other |
Direct Interaction | yes |
n/a |
Trial Name | LFB-R603 |
Novel drug target | Established target |
n/a |
Mechanism of Interaction | B-lymphocyte antigen CD20 binding agent |
Direct Interaction | yes |
antibody (inhibitory) |
antibody (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | B-lymphocyte antigen CD20 inhibitor |
Direct Interaction | yes |
Trial Name | Rituxan |
MS4A1 | Ensembl Gene Name |
Gene Biotype | PROTEIN_CODING |
MS4A1 | Gene Symbol |
Target Class | Miscellaneous |
Target Subclass | MS4A family |
Target Class | Other |
P11836 | Uniprot Accession |
MS4A1 | Gene Symbol |
CD20_HUMAN | Uniprot Id |
Target Subclass | Unknown_function |
Target Main Class | Other |
Target Subclass | MS4A |
PA31111 | PharmGKB ID |
CD20 | TTD Gene Abbreviation |
T73215 | TTD Target ID |
931 | Entrez Gene Id |
MS4A1 | MyCancerGenome Gene Symbol |
CD20 | MyCancerGenome Reported Gene Name |
CD20 | GENE_SYMBOL |
MS4A1 | GENE_SYMBOL |
B-lymphocyte antigen CD20 | UNIPROT |
ENSG00000156738 | Gene Symbol |
MS4A1 | Ensembl Id |
DRUGGABLE GENOME |
CD20 | GO Gene Synonym |
CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE |
MS4A1 | Gene Symbol |
CLINICALLY ACTIONABLE |